Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community
D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results
D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals
D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach
D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children
D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels
D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results
D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency
D1.422 - A service review of the complex COVID-19 vaccination service
D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report
D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic
D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic
D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome
D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023
D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters
D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch
D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria
D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway
D2.300 - Fixed Drug Eruption related to the use of NSAIDs
D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download